An Open-label, Single-dose Study of the Safety, Tolerability, and Pharmacokinetics of AMG 423 in Healthy Subjects and Subjects With Various Degrees of Renal Insufficiency and Effect of Hemodialysis on AMG 423 Pharmacokinetics
Latest Information Update: 02 Nov 2021
At a glance
- Drugs Omecamtiv mecarbil (Primary)
- Indications Heart failure
- Focus Pharmacokinetics
- Sponsors Amgen; Cytokinetics
- 17 Sep 2021 Results presented at the 2021 American College of Clinical Pharmacology Annual Meeting
- 26 Mar 2021 Results published in the Clinical Pharmacokinetics.
- 26 Mar 2021 Status changed from recruiting to completed.